




Extended Data Figure 8. In vivo efficacy of FOLR1-directed CAR T. (Related to Fig. 4) **a.** Quantification of leukemia burden over time based on IVIS radiance in CBFA2T3-GLIS2-transduced HSPCs, WSU-AML, Kasumi-1 FOLR1+ and Kasumi-1 xenografts treated with unmodified or FOLR1 CAR T cells at 5×10^6 /mouse. Leukemia burden is shown for each mouse. N = 5 mice per group. **b.** Quantification of human T cells in the mouse peripheral blood at indicated time points after T cell injection. Shown is human CD45+CD3+ frequency amongst DAPI- cells. N = 5 mice per group. Data presented are the average $\pm$ standard deviation from 5 mice. *, $p < 0.05$ (unpaired Student's t-test) **c.** Kaplan-Meier survival curves of xenografts treated with unmodified or FOLR1 CAR T cells. N=5 per group. Statistical differences in survival were evaluated using Log-rank Mantel-Cox. Note: 2 C/G-CB-bearing mice treated with CAR T cells died without leukemia and T cells present in bone marrow, spleen and liver tissues and in peripheral blood as determined by flow cytometric analysis.